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 23 
ABSTRACT 24 
The increasing incidence and severity of infection by Clostridium difficile has stimulated 25 
attempts to develop new antimicrobial therapies. We report here the relative abilities of 26 
two antibiotics (metronidazole and vancomycin) in current use for treating C. difficile 27 
infection and a third antimicrobial, surotomycin, to kill C. difficile cells at various stages 28 
of development and to inhibit the production of the toxin proteins that are the major 29 
virulence factors. The results indicate that none of the drugs affects the viability of 30 
spores at 8X MIC or 80X MIC and that all of the drugs kill exponential phase cells when 31 
provided at 8X MIC. In contrast, none of the drugs killed stationary phase cells or 32 
inhibited toxin production when provided at 8X MIC and neither vancomycin nor 33 
metronidazole killed stationary phase cells when provided at 80X MIC. Surotomycin, on 34 
the other hand, did kill stationary phase cells when provided at 80X MIC, but did so 35 
without inducing lysis.  36 
 37 
INTRODUCTION 38 
 39 
In the United States, the incidence of Clostridium difficile infection (CDI) has been 40 
steadily rising over the last 15-20 years (1-3). There has been a significant increase in 41 
primary, recurrent and untreatable CDI on a global scale as well (3, 4). Treatment with 42 
oral vancomycin or metronidazole, the current standard practice, leads to recurrence of 43 
CDI in up to 30% of patients treated for an initial episode. For patients that have already 44 
suffered multiple recurrences, the future recurrence rate can be as high as 60% (3, 5-7). 45 
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In addition, many cases of CDI in the US are now linked to a family of more virulent 46 
strains (NAP1/BI/027) that emerged first in the UK and then in Canada (8, 9).  47 
 48 
C. difficile spores, the infectious form of the organism, are metabolically dormant but 49 
germinate in response to a combination of host-derived bile acids and glycine (10).  50 
Because spores are metabolically dormant, they are insensitive to the action of most 51 
antibiotics.  Thus, after antibiotics are prescribed to treat the active infection, the spores 52 
that remain in the colon or that are acquired from the environment are able to germinate 53 
and re-initiate active infection.  The process of spore germination is largely enzymatic 54 
and, once initiated, cannot be stopped.  Once stimulated to germinate, the spore 55 
releases a large depot of dipicolinic acid, chelated 1:1 with Ca++ (CaDPA), in exchange 56 
for water (11).  Also, the cortex layer, a specialized peptidoglycan, is degraded (12, 13).  57 
After these changes, the spore is no longer dormant and does not have the resistances 58 
typically characteristic of a spore.  Metabolism then resumes within the spore core and 59 
a vegetative cell grows out from the germinated spore.  Such outgrowth is susceptible to 60 
the action of several antibiotics (14). Moreover, the host intestine contains an 61 
assortment of antimicrobial compounds that are produced by the innate immune system 62 
and the host microbiota. To combat these defenses, C. difficile can modify its cell wall to 63 
resist antimicrobials or efflux a variety of antimicrobial peptides from the cell (15-17). 64 
These resistance mechanisms allow C. difficile to grow in the presence of antimicrobial 65 
peptides and may also contribute to resistance to therapeutic antimicrobials.    66 
 67 
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Given the difficulties in treating C. difficile infections, the identification of narrow-68 
spectrum antibiotics that are potent inhibitors of C. difficile growth would fulfill a critical 69 
need.  Also needed are compounds or methods of reducing spore abundance or 70 
viability in order to limit the onset of infection and to prevent relapsing disease.  Here we 71 
investigated the activities of a newly-developed antibiotic, surotomycin (18, 19), and 72 
compared its activity to that of metronidazole and vancomycin, two antibiotics that are 73 
currently used for treatment of C. difficile infections. Surotomycin is a lipopeptide 74 
antibiotic that acts through depolarization of the membrane, leading to the loss of a 75 
proton gradient and cell death (19).  The mechanism of action of surotomycin differs 76 
significantly from that of vancomycin (cell wall synthesis-inhibiting) and metronidazole 77 
(inhibition of cellular enzymatic functions), suggesting that surotomycin may affect C. 78 
difficile physiology differently than do these other antibiotics. We report here the relative 79 
sensitivities of C. difficile strains to surotomycin, metronidazole and vancomycin at 80 
multiple stages of the life cycle, i.e., as dormant (phase-bright) spores, as germinated 81 
(phase-dark) spores, as exponential phase cells and as stationary phase cells. In 82 
addition, we assessed the effects of the antibiotics on toxin gene expression and 83 
measured the effects of various mutations that affect the sensitivity of exponential 84 
phase cells to nisin (an antibiotic that creates holes in membranes and disrupts cell wall 85 
synthesis) on susceptibility to the three tested compounds. 86 
 87 
MATERIALS AND METHODS 88 
 89 
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Strains used and growth conditions. Clostridium difficile strains UK1 (ribotype 027; 90 
provided by Dr. D. Gerding) (20) and JIR8094 (ribotype 012; provided by Dr. J. Rood) 91 
were routinely grown at 37ºC in brain heart infusion (BHI) medium supplemented with 92 
cysteine (0.1%) and yeast extract (0.5%), referred to here as BHIS, or in tryptose-yeast 93 
extract medium (3% tryptose, 2 % yeast extract, 0.1% thioglycollate), referred to as TY. 94 
All growth experiments were performed in Coy anaerobic chambers in an atmosphere 95 
containing 85% nitrogen, 10% hydrogen, and 5% carbon dioxide as previously 96 
described (21, 22). Susceptibility testing of surotomycin requires the presence of 50 mg 97 
(2.5 mEq) Ca++ per liter in the medium (23). The levels of Ca++ in the media used were 98 
determined by Laboratory Specialists Inc; following their instructions, the Ca++ 99 
concentration in all media was raised to 50 mg/L by addition of CaCl2.2H20.  Drugs were 100 
added where indicated. Surotomycin was provided by Cubist Pharmaceuticals. 101 
Metronidazole and vancomycin were purchased from Sigma-Aldrich. Nisin was obtained 102 
from MP Biomedicals. 103 
 104 
The following mutant strains derived from JIR8094 were used in this study: MC112, a 105 
lytC (peptidoglycan hydrolase), nisin-tolerant mutant; MC119, a spontaneous cprK 106 
(nisin-resistant) mutant with increased resistance to lantibiotics and polymyxin B (16); 107 
MC120, a mutant with a TargeTron insertion in dltD resulting in increased susceptibility 108 
to nisin and polymyxin B (15); and, MC141, a mutant with a TargeTron insertion in cprA 109 
causing increased susceptibility to lantibiotics (16).  110 
 111 
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Minimal Inhibitory Concentrations. Minimal inhibitory concentrations (MICs) were 112 
determined by growth of bacteria in culture tubes or in 96-well plates (that had been 113 
pre-reduced for at least 24 hrs prior to use) in media (either BHIS or TY) supplemented 114 
with 2-fold serial dilutions of the test compounds. The initial bacterial titer was 5 x 105 115 
colony-forming units (CFU) per ml. Each strain and each drug concentration was tested 116 
in duplicate in each MIC assay. The MIC was determined as the lowest concentration of 117 
drug at which no bacterial growth was detected after 18-24 hrs at 37°C. MIC assays 118 
were performed at least 3 times to ensure reproducibility of results. 119 
 120 
Spore germination assay. Spores of C. difficile strain UK1 were produced and purified 121 
as described previously (14, 24, 25).  Purified spores (1 x 107) were suspended in 1 mL 122 
BHIS medium or germination salts [0.3 mM (NH4)2SO4, 6.6 mM KH2PO4, 15 mM NaCl, 123 
59.5 mM NaHCO3, and 35.2 mM Na2HPO4] supplemented with 10 mM glycine. Cultures 124 
were further supplemented with 2 mM taurocholic acid (TA) and the test compounds at 125 
8X or 80X MIC. The initiation of spore germination was detected as the loss of optical 126 
density at 600 nm in a PerkinElmer Lambda 25 spectrophotometer. 127 
 128 
Measurements of killing rates. For experiments involving phase-dark spores, 1 x 107 129 
phase-bright spores of strain UK1 were first incubated for 10 minutes in BHIS medium 130 
supplemented with 2 mM TA.  The suspension was then centrifuged for 1 min at 14,000 131 
x g.  The resulting pellet of phase-dark spores was suspended in BHIS medium at a 132 
concentration of 1 x 105 per ml with or without the test compounds at 8X MIC or 80X 133 
MIC in Teflon-coated tubes to prevent the adherence of spores to the tubes. Spores 134 
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were confirmed to be phase-dark by phase-contrast microscopy. For experiments using 135 
exponential phase vegetative cells, strains UK1 or JIR8094 (1 x 105 per ml) were 136 
suspended in BHIS medium supplemented with CaCl2 with or without addition of the 137 
test compounds at 8X MIC for strain JIR8094 or at 8X MIC and 80X MIC for strain UK1. 138 
For stationary phase cell killing assays, strain UK1 was grown in TY medium for ~12 139 
hours and then diluted in 30 ml TY supplemented with CaCl2 to give an OD600~0.1. After 140 
12 hrs incubation at 37°C, at which point the cells had left exponential growth phase, 141 
the culture was subdivided and the test compounds were each added to a separate 142 
culture tube at 8X or 80X MIC. For all assays, samples were withdrawn at indicated time 143 
points thereafter and viability was scored by plating serial dilutions on BHIS agar without 144 
calcium or antibiotic. Plates were incubated in the anaerobic chamber overnight. Each 145 
killing rate assay was performed at least twice to ensure reproducibility of the results. 146 
 147 
Measurements of toxin gene expression. An overnight culture of strain UK1 was 148 
diluted in 30 ml TY-Ca++ to give an OD600~0.1. After 12 hrs incubation at 37°C, the 149 
culture was split and each test compound was added to a separate subculture at 8X 150 
MIC. (Toxin gene expression was not tested in cells exposed to drugs at 80X MIC 151 
because such treatment with surotomycin at that concentration led to cell death and 152 
prevented the isolation of intact mRNA.) RNA was prepared from cells harvested at 0, 2, 153 
4, 8 and 24 hrs after addition of the drugs as previously described (26). RNA was 154 
quantified by absorbance using a NanoDrop ND-1000 spectrophotometer (Thermo 155 
Scientific). Primers for qPCR were designed using the online PrimerQuest tool from 156 
Integrated DNA Technologies 157 
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(http://www.idtdna.com/Scitools/Applications/Primerquest). Synthesis of cDNA was 158 
performed on 500 ng of RNA using random hexamer primers and the QuantiTect® 159 
Reverse Transcription Kit (QIAgen) according to the manufacturer’s recommendations. 160 
To control for chromosomal DNA contamination, mock cDNA synthesis reactions 161 
containing no reverse transcriptase were used as negative controls in subsequent 162 
amplifications. cDNA samples were diluted 4-fold and used as templates for qPCR of 163 
rpoC (primers oLB122 [CTAGCTGCTCCTATGTCTCACATC] and oLB123 164 
[CCAGTCTCTCCTGGATCAACTA]) and tcdA (primers oLB131 165 
[GTATGGATAGGTGGAGAAGTCA] and oLB132 166 
[CTCTTCCTCTAGTAGCTGTAATGC]) using the Roche SYBR Green I PCR mix and a 167 
Roche LightCycler 480 II thermocycler. Reactions were performed in a final volume of 168 
20 µl using 4 µl diluted cDNA and primers at 1 µM final concentration. Amplification 169 
included 45 cycles of the following steps: 10 s at 95 °C, 10 s at 52 °C, 15 s at 72 °C. 170 
Reactions were performed in triplicate using cDNA synthesized from each of a minimum 171 
of three biological replicates, and results are presented as the means and SEM of the 172 
data obtained. Results were calculated using the 2-delta deltaCt method, in which the 173 
amount of target mRNA is normalized to that of an internal control transcript (rpoC) (27). 174 
 175 
Measurements of toxin protein accumulation by ELISA. Culture supernatants of the 176 
samples used for RNA extraction (above) were assayed for toxin A levels by ELISA (28). 177 
In brief, 96-well plates were coated with antibody to toxin A (Novus Biologicals) 178 
overnight at 4°C. After washing with PBS containing 0.1% Tween 20, the plates were 179 
incubated with blocking agent and, after discarding the agent, incubated with culture 180 
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fluid samples with or without dilution for 1 hr at room temperature. After washing with 181 
PBS-Tween, the plates were incubated with secondary antibodies fused to HRP (Gallus 182 
Immunotech, Inc.). After 1 hr at room temperature, the plates were washed again with 183 
PBS-Tween and mixed with peroxidase substrate for 40 min at room temperature. The 184 
reactions were stopped with H2SO4 and the OD450 was determined using a plate reader.  185 
Standard curves were generated using purified recombinant toxin A (29).  186 
 187 
RESULTS  188 
 189 
Determining the MICs of the test compounds. The MICs for each of the test 190 
compounds were determined using exponential phase cells as the target. The MIC 191 
values varied according to the strain being tested and the growth medium used (Table 192 
1). For all further experimentation, the concentration of each antibiotic used was based 193 
on the MIC of that antibiotic in the strain to be tested growing in the medium being used. 194 
The growth medium chosen for each experiment was based on previous experimental 195 
conditions. 196 
 197 
MIC determination in mutant strains. A panel of mutant strains derived from JIR8094 198 
and altered in susceptibility to nisin and other small, cationic antimicrobial peptides 199 
(CAMPs) was tested for their susceptibility to surotomycin, metronidazole and 200 
vancomycin. As shown in Table 2, all strains had identical MIC values for metronidazole, 201 
but the MIC values for surotomycin and vancomycin varied slightly. MC112 has a 202 
mutation in an autolysin that presumably alters the cell wall of the bacterium, resulting in 203 
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increased tolerance to nisin, though not a higher MIC value. (That is, MC112 survives 204 
exposure to higher concentrations of nisin than does the parent strain, but does not 205 
grow in the presence of nisin.) MC112 had similar growth to the wild-type parent in all 206 
antibiotics tested, including surotomycin, in which the strain grew at a 2-fold higher 207 
concentration.  208 
 209 
MC119 carries a mutation in a regulatory protein that is known to control an ABC-210 
transporter system (cprABC). As a result, the MC119 mutant has an extraordinarily high 211 
MIC value for growth in nisin. In a previous study, we determined that MC119 also is 212 
less susceptible to polymyxin B (16).  The MC119 strain had a 2-fold higher MIC for 213 
both vancomycin and surotomycin. The strongly decreased susceptibility of MC119 to 214 
vancomycin and its modestly decreased susceptibility to surotomycin, and polymyxin B 215 
are consistent with the hypothesis that this mutant is altered in its response to 216 
antimicrobials that target the cell surface.  217 
 218 
Effects of antibiotic exposure on the initiation of C. difficile UK1 spore 219 
germination. To test if surotomycin or vancomycin or metronidazole is able to affect C. 220 
difficile spore germination, purified spores of strain UK1 were incubated in BHIS-Ca++ 221 
with or without the germinant taurocholate (TA) (10) and with or without each of the 222 
antibiotics. The spores germinated, as measured by loss of OD600, when suspended in 223 
BHIS-Ca++ supplemented with 2 mM TA, but not in the absence of TA (Figure 1A – D). 224 
(The loss of OD corresponds to the conversion of spores from a birefringent [phase-225 
bright] form to a non-birefringent [phase-dark] form.) The addition of surotomycin or 226 
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metronidazole or vancomycin at 8x or 80x MIC had no effect, either positive or negative, 227 
on TA-dependent spore germination (Figure 1A – D). When similar experiments were 228 
performed in a buffer containing TA and glycine, a co-germinant, the same lack of effect 229 
of the antibiotics was seen (data not shown). 230 
 231 
Effects of antibiotic exposure on germinated (phase-dark) spores. To determine 232 
the time after spore germination at which outgrowing vegetative cells become sensitive 233 
to the antibiotics, we added antibiotics to germinated (phase-dark) spores in BHIS-Ca++ 234 
and followed bacterial viability at intervals thereafter. When exposed to surotomycin, the 235 
outgrowing cells lost viability more rapidly than after exposure to the other drugs (Table 236 
3). Note that this experiment does not distinguish between the time needed for killing 237 
and the growth stage at which outgrowing vegetative cells become susceptible to the 238 
drugs. 239 
 240 
Effects of surotomycin, metronidazole and vancomycin on exponential-phase 241 
cells. Strains UK1 and JIR8094 were grown at 37°C to early exponential phase in 242 
BHIS-Ca++. After determining the initial titer, the cultures were divided and inoculated 243 
with the test drugs at concentrations corresponding to 8X or 80X MIC. Samples of each 244 
culture were taken at multiple time points and surviving cell titers were determined by 245 
serial dilution and plating on BHIS-Ca++ supplemented with taurocholic acid (TA). In 246 
exponential phase cells of strain UK1, surotomycin reduced viability by 90% more 247 
rapidly than did the other drugs (Table 3). In exponential phase cells of strain JIR8094, 248 
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surotomycin, metronidazole and nisin were all rapid killers, whereas vancomycin 249 
reduced viability more slowly (Fig. 2). 250 
 251 
Effects of surotomycin, metronidazole and vancomycin on stationary phase cells. 252 
After incubation of a culture of strain UK1 in TY + CaCl2 at 37°C for 12 hrs, the culture 253 
was split and each drug was added to a separate culture tube at 8X or 80X MIC. 254 
Samples were harvested at various intervals for CFU counts and OD600 readings. At 8X 255 
MIC, none of the three drugs reduced the turbidity of the culture (apparent cell mass) or 256 
viability substantially (Figs. 3A and 4A). At 80X MIC, however, surotomycin greatly 257 
diminished viability (but not cell mass significantly, indicating killing without cell lysis), 258 
whereas vancomycin and metronidazole had no detectable impact on cell mass or 259 
viability (Figs. 3B and Fig. 4B). 260 
 261 
Effects of surotomycin, metronidazole and vancomycin on toxin gene expression 262 
and toxin release. To test the effects of the various drugs on toxin production, cells at 263 
an early stage of stationary phase were exposed to the individual compounds at 8X MIC. 264 
At intervals thereafter, samples were harvested and RNA was extracted for quantitation 265 
by qRT-PCR. As shown in Fig. 5, expression of tcdA, the gene that encodes toxin A, 266 
increased with time to similar extents in untreated cells and cells treated with drugs. 267 
 268 
To measure toxin A release into the culture medium, the supernatant fluids of the 269 
samples used above for RNA extraction were assayed for toxin A levels by ELISA (see 270 
Materials and Methods). Standard curves were generated using purified toxin A. As 271 
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shown in Fig 6, the amount of toxin A in the culture fluid was not significantly altered 272 
compared to the no-drug control by exposure to surotomycin or metronidazole at 8x 273 
MIC at early stationary phase. Addition of vancomycin, however, reduced toxin release 274 
at 24 hrs. 275 
 276 
DISCUSSION 277 
 278 
The results presented here show that surotomycin kills cells that are growing out of 279 
germinated spores, exponential-phase cells and stationary-phase cells (in the latter 280 
case at 80X MIC only) of strain UK1 more rapidly than does metronidazole or 281 
vancomycin. Surotomycin is also a more rapid killer of exponential-phase cells of strain 282 
JIR8094 than is vancomycin. None of the antibiotics tested was able to inhibit or 283 
activate C. difficile spore germination. This result seems to fit with the mechanisms of 284 
action of the tested antibiotics.  The initiation of spore germination, a mostly enzymatic 285 
process, would be unaffected by antibiotics that need to be metabolized before 286 
becoming potent (metronidazole) or by antibiotics that inhibit new cell wall synthesis 287 
(vancomycin).  Surotomycin leads to loss of the proton gradient, but does so by 288 
depolarizing the membrane without causing permeability of molecules as large as 671 289 
daltons (19). Such a mechanism might explain its lack of effect on the initiation of spore 290 
germination if the pores created are also not large enough to allow the escape of Ca++-291 
DPA from the spore core, a step necessary for the completion of germination (12, 13).  292 
Alternatively, surotomycin might be unable to penetrate the spore coat and cortex in 293 
order to gain access to the spore inner membrane. 294 
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  295 
Since outgrowing spores are metabolically active and synthesize new cell wall 296 
peptidoglycan, it is not surprising that such spores are susceptible to all of the 297 
antibiotics tested, although the heightened susceptibility of such cells to surotomycin 298 
was not predictable. The greater activity of surotomycin may be due to its ability to 299 
prevent the generation of a proton gradient needed for metabolic functions to resume. 300 
After the loss of dormancy, metabolism resumes in the core.  Subsequently, a 301 
vegetative cell begins to grow from the germinated spore and this requires new cell wall 302 
synthesis.  Metronidazole, which requires cellular metabolism for activity (30), inhibited 303 
growth in an intermediate time-frame with respect to surotomycin and vancomycin.  304 
Because new cell wall synthesis occurs late during outgrowth, it is not surprising that 305 
vancomycin required more time to inhibit growth than the other two antibiotics tested. 306 
 307 
Although the ability of all three antibiotics to kill exponential phase cells was expected, 308 
their differential effects on stationary phase cells suggest that surotomycin may be more 309 
effective than vancomycin or metronidazole in reducing the severity and recurrence of 310 
infection. That is, at 80X MIC, a relatively low dose compared to those used clinically, 311 
surotomycin killed stationary phase cells rapidly. Since stationary phase cells are the 312 
ones that form spores and produce toxins, a drug that kills both exponential and 313 
stationary phase cells may be particularly effective in reducing the spore titer and toxin 314 
levels in the colon and in stool. 315 
 316 
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The appearance of C. difficile mutants that have decreased susceptibility to surotomycin 317 
is rare and the MIC shift is not more than 8-to-16 fold (18). Therefore, it is interesting 318 
that certain mutant strains that were isolated on the basis of their increased tolerance or 319 
resistance to nisin also showed slightly reduced susceptibility to surotomycin (Table 2). 320 
The basis for this decreased sensitivity is not known, but is likely to reflect changes in 321 
cell surface architecture. The decrease in susceptibility gained, however, would not be 322 
expected to influence the effectiveness of surotomycin in vivo.  323 
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FIGURE LEGENDS 421 
Figure 1. Effect of antibiotic treatment on initiation of C. difficile spore 422 
germination. 423 
C. difficile UK1 spores were suspended in BHIS-Ca++ medium (black) or medium 424 
supplemented with 8x MIC (A) or 80x MIC (B) surotomycin or 8x MIC (C) or 80x (D) 425 
vancomycin or metronidazole.  Where indicated, the medium was supplemented with 426 
taurocholic acid (TA), an activator of germination. The initiation of spore germination 427 
was detected by measuring the loss of OD600. Experiments were performed in duplicate; 428 
the presented data represent one such experiment.  Germination plots from the two 429 
experiments were superimposable.  430 
Figure 2. Effects of drugs at 8X MIC on survival of exponential phase cells of C. 431 
difficile strain JIR8094.  432 
Exponential phase cultures (OD600 = 0.45) in BHIS-Ca++ were exposed to the three 433 
antibiotics and samples withdrawn at indicated times thereafter were assayed for 434 
viability (CFU/ml).  435 
Figure 3. Effects of drugs on stationary phase cells of strain UK1 as measured by 436 
cell mass. 437 
Panel A, each drug was added at 8X MIC to the cultures at early stationary phase; 438 
panel B, each drug was added at 80X MIC to the cultures at early stationary phase. At 439 
least 3 biological replicates were performed for each drug at each concentration. 440 
Figure 4. Effects of drugs at 8X and 80X MIC on viability of strain UK1 stationary 441 
phase cells. Early stationary phase cells were exposed to antibiotics at 8X MIC (part A) 442 
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or 80X MIC (part B). At indicated time-points thereafter, samples were removed and 443 
plated for viable counts (CFU). 444 
Figure 5. qRT-PCR analysis of tcdA expression following treatment with 445 
surotomycin, metronidazole or vancomycin at 8X MIC. Strain UK1 was grown in 446 
CaCl2-supplemented TY medium for ~12 hrs as described above, at which time the 447 
culture was split and drugs were added at 8X MIC. At two, four, eight and twenty-four 448 
hrs after addition of drugs, cell samples were harvested, RNA was extracted, and cDNA 449 
was synthesized as described under Materials and Methods. cDNA corresponding to 450 
tcdA mRNA was quantified by real time-PCR. Reactions were performed in triplicate 451 
using cDNA synthesized from each of a minimum of three biological replicates, and 452 
results are presented as the means and SEM of the data obtained. Results were 453 
calculated using the 2-delta deltaCt method, in which the amount of target mRNA was 454 
normalized to that of an internal control transcript (rpoC). 455 
Figure 6. ELISA assays of toxin A in cultures of strain UK1 treated with 456 
surotomycin, metronidazole or vancomycin at 8X MIC. Culture fluids of cells 457 
exposed to antibiotics at early stationary phase were collected at the indicated times 458 
and assayed for toxin A by ELISA. 459 
 460 
 461 
 462 
 463 
 464 
  465 
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Table 1. MIC values for antimicrobial compoundsa 466 
 467 
MIC (µg/ml) 
Strain (Growth Medium) Surotomycin Metronidazole Vancomycin 
UK1 (BHIS + Ca++) 1.5 0.5 0.3125 
JIR8094 (BHIS + Ca++) 1 0.5 2 
UK1 (TY + Ca++) 0.125 0.125 1 
ATCC 70057 (TY + Ca++) 0.125-0.25 0.06-0.125 1 
 468 
a The various strains were grown in the indicated media and assayed for susceptibility 469 
to the indicated antibiotics provided in a series of two-fold dilutions. The MIC was  470 
defined as the lowest concentration of antibiotic that prevented measurable growth. 471 
  472 
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Table 2.  MIC values for antimicrobial compounds on mutant strainsa 473 
 474 
 475 
 476 
 477 
 478 
 479 
 480 
 481 
 482 
a Each strain and each drug concentration was tested in cells growing in BHIS medium 483 
in duplicate for each assay. Assays were performed at least 3 times to ensure 484 
reproducibility of results. 485 
Strain 
 
MIC (μg/ml) 
Nisin Surotomycin Metronidazole Vancomycin 
JIR8094 180 1 0.5 2 
MC112 180 2 0.5 2 
MC119 1440 2 0.5 4 
MC120 90 1 0.5 2 
MC141 90 1 0.5 2 
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Table 3. Time required to reduce viability of C. difficile UK1 phase-dark spores and exponential-phase cells by 486 
90%. 487 
Time to 90% Killing in Hours 
 8x MIC 80x MIC 
Surotomycin Metronidazole Vancomycin Surotomycin Metronidazole Vancomycin 
UK1 phase-dark sporesa 3.33 > 7 > 7 2 3 > 5  
UK1 exponential-phase cellsb 0.33 1.5 1.5 < 0.33 0.66 1.33 
a Tubes containing BHIS medium supplemented with CaCl2 and the indicated antibiotics (at 8X MIC or 80X MIC) were 488 
inoculated with phase-dark spores of strain UK1 and tested, after various times of incubation, for survival by plating on 489 
BHIS medium.   490 
b Exponential-phase cells of strain UK1 growing in BHIS medium supplemented with CaCl2 were exposed to two different 491 
concentrations (8X MIC and 80X MIC) of the indicated antibiotics. Survival was assayed by plating serial dilutions on 492 
BHIS-Ca++ medium. 493 
 494 
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